<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04014764</url>
  </required_header>
  <id_info>
    <org_study_id>N-01</org_study_id>
    <nct_id>NCT04014764</nct_id>
  </id_info>
  <brief_title>Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy</brief_title>
  <acronym>(ANSWer)</acronym>
  <official_title>An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Notable Labs</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Notable Labs</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter observational study to collect clinically annotated
      biospecimens in order to assess the correlation between ex vivo data generated by the Notable
      assay platform and clinical outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, observational study with collection of de-identified
      biospecimens with matched clinical data from up to 1000 participants from clinical networks
      in the United States and Canada. Clinical information, demographics, and medical data
      relevant to cancer status are collected from all participants and their medical record at
      baseline (at study entry and time of baseline biospecimen collection), and subsequent visits
      per patient consent, for up to 1 year.

      The primary assessment is the establishment of a tumor registry with annotated clinical
      outcomes. Exploratory assessments include correlation of ex vivo functional testing results
      with clinical outcomes, as well as identification of potential biomarkers that correlate
      responses with genotype and/or phenotype.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2019</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Clinical response to treatment</measure>
    <time_frame>3 years</time_frame>
    <description>Collect clinical responses to treatment and outcomes in patients who have provided samples to the biobank</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type of clinical treatment responses</measure>
    <time_frame>3 years</time_frame>
    <description>Correlate ex vivo drug sensitivity data on patient samples with clinical treatment responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Types of somatic tumor mutations</measure>
    <time_frame>3 years</time_frame>
    <description>Determine genotype and/or phenotype relationships between ex vivo and clinical responses with somatic tumor mutations.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Lymphoma</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Myeloproliferative Neoplasm</condition>
  <arm_group>
    <arm_group_label>Single group</arm_group_label>
    <description>Documented hematologic malignancy in need of starting an active anti-cancer therapy.
This is a non-interventional study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>This is a non-interventional study</intervention_name>
    <description>N/A. This is a non-interventional study. Following consent, the subject will have biospecimen samples taken during routine standard of care procedures, and provided to Sponsor for analysis. Optional research blood draws may occur at treating physician's discretion to obtain additional tissue samples.</description>
    <arm_group_label>Single group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The study will require tissue samples taken from consented subjects to be assayed using
      Notable's ex vivo, high-throughput flow cytometry based platform. The result of this assay
      will be compared to the subject's documented diagnosis as well as clinical outcome, where
      applicable. Additional biomarker testing, such as sequencing to determine somatic mutations
      using targeted panels, may also be conducted.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Approximately 1000 Subjects with diagnosed with a hematological malignancy will be enrolled
        to provide at least 1000 biospecimen samples.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written informed consent;

          -  Age ≥ 18 years, male or female, of any race;

          -  Documented hematologic malignancy (any of the below) in need of starting an active
             anti-cancer therapy:

          -  Acute myelogenous leukemia (AML)

          -  Multiple myeloma (MM)

          -  Myelodysplastic syndrome (MDS)

          -  Lymphoma

          -  Acute lymphocytic leukemia (ALL)

          -  Chronic lymphocytic leukemia (CLL)

          -  Chronic myelogenous leukemia (CML)

          -  Neoplasm (MPN)

          -  Other (upon review and approval by medical monitor)

        Note: *Supportive care agents including erythropoiesis-stimulating agents (ESAs) such as
        EPO, Procrit, Aranesp, etc; granulocyte colony stimulating factor (G-CSF); hydroxyurea
        (Hydrea); and luspatercept (Reblozyl) are not considered anti-cancer therapy for this study

          -  Intent to start anti-cancer therapy within 21 days of biospecimen collection

             •≥7 days from last anti-cancer therapy;

          -  Any number of prior therapies

          -  Subject cohort is currently open

        Exclusion Criteria:

          -  Unwilling or unable to give consent

          -  Subject's disease is in remission

          -  Subject cohort is not open at time of consent

          -  Subject is restarting an ongoing treatment regimen after a dose interruption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroomi Tada, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Notable Labs</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Donna M Stram</last_name>
    <phone>9783400869</phone>
    <email>DONNA@CHIMERACLINICAL.COM</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susanna Wen</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CBCC Global Research</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rose Perez</last_name>
      <phone>661-862-7178</phone>
    </contact>
    <investigator>
      <last_name>Pradip Rustagi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Kanamori, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ravindranath Patel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristi Mendez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susana Bell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathy Jo Robb, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Central Coast Health Centers -- SLO Oncology and Hematology Health Center</name>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <zip>93401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Hidalgo</last_name>
      <phone>805-543-5577</phone>
      <email>Amy.hidalgo@dignityhealth.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Spillane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Link, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gorgun Akpek, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diane DeVos-Schmidt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colorado West Healthcare System, dba Grand Valley Oncology</name>
      <address>
        <city>Grand Junction</city>
        <state>Colorado</state>
        <zip>81505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandy Martin</last_name>
      <phone>970-644-3180</phone>
      <email>gvoclinicaltrials@gjhosp.org</email>
    </contact>
    <investigator>
      <last_name>Jonathan King, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joanne Virgilio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sudy Jahangiri</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathryn Tarman</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diane Melancon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Liggett</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristina Goutsouliak</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ocala Oncology Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjit Nirmalanandhan</last_name>
      <phone>352-547-1958</phone>
      <email>Sanjit.nirmalanandhan@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Anju Vasudevan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rama Balaraman</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ketan Doshi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorelly Mobley</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samuel Myrick</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Sinquefield</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid Florida Hematology and Oncology Center</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahesh Nelakurthi</last_name>
      <phone>386-774-1223</phone>
      <email>mahesh@aorcorp.com</email>
    </contact>
    <investigator>
      <last_name>Santosh Nair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bushra Ajaz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renee Cabeza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Niraj Sharma, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Banu Visvalingam, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Roche, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern Light Cancer Care Center</name>
      <address>
        <city>Brewer</city>
        <state>Maine</state>
        <zip>04412</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurie Lewis, RN</last_name>
      <phone>207-973-7478</phone>
      <email>llewis@northernlight.org</email>
    </contact>
    <contact_backup>
      <last_name>Rong Zhang</last_name>
      <phone>207-973-9763</phone>
      <email>rzhang@northernlight.org</email>
    </contact_backup>
    <investigator>
      <last_name>Astrid Andreescu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Allan-Louis Cruz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>A. Merrill Garrett, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diana Porter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Beth Sypher, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Danielle Fogg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janice Pilotte, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Debasmita Saha, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ellen Arey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zarah Dulce Lucas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sheila Karina Pascual, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Chodkiewicz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sigrid Berg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Sinclair, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Lindner Center for Research and Education at The Christ Hospital -- The Cancer Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Woste, RN</last_name>
      <phone>513-585-0844</phone>
      <email>Lisa.woeste@thechristhospital.com</email>
    </contact>
    <investigator>
      <last_name>Gina Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Cody, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bhandari Manish, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irfan Firdaus, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Mannion, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Slobodan Stanisic, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jamie Waselenko, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Weipang Zhang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.n01answer.com</url>
    <description>Site Feasibility Questionnaire, public study information</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 3, 2019</study_first_submitted>
  <study_first_submitted_qc>July 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2019</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

